Vanda Pharmaceuticals Inc.
Financials
Valuation Metrics
Vanda Pharmaceuticals Inc.'s Market Cap is $233M. At end of 2025 it was $521M. Ranked #2944 of 3,115 in US market (top 95%), #1338 of 1,472 on NASDAQ (top 91%), #237 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $233M | US#2,944/3,115 Sec#237/265 |
| Revenue | $229M | US#2,534/3,115 Sec#108/265 |
| Net Income | $-275M | US—/3,115 Sec—/265 |
| Total Assets | $382M | US#2,828/3,115 Sec#180/265 |
| Net Assets | $200M | US#2,641/3,115 Sec#179/265 |
| Employees | 533 | US#2,247/3,115 Sec#79/265 |
| Value | ||
| P/B | 1.17x | US#493/3,115 Sec#26/265 |
| P/S | 1.02x | US#792/3,115 Sec#14/265 |
| FCF Yield | -38.37% | US—/3,115 Sec—/265 |
| Profitability | ||
| ROE | -137.51% | US#2,805/3,115 Sec#208/265 |
| ROA | -71.88% | US#3,023/3,115 Sec#236/265 |
| Op. Margin | -77.59% | US#2,697/3,115 Sec#118/265 |
| Revenue Growth | 8.11% | US#1,665/3,115 Sec#109/265 |
| Financial Health | ||
| Debt Ratio | 91.30% | US#959/3,115 Sec#159/265 |
| Total Debt | $17M | US#2,732/3,115 Sec#183/265 |
| FCF | $-90M | US#2,710/3,115 Sec#175/265 |
| Cash | $62M | US#2,537/3,115 Sec#218/265 |
| Current Ratio | 1.54x | US#1,543/3,115 Sec#233/265 |
| Performance | ||
| 1Y Return | -10.80% | US#2,541/3,115 Sec#203/265 |
| 1M Return | -16.20% | US#2,833/3,115 Sec#230/265 |
| From 52W High | -60.97% | US#2,848/3,115 Sec#224/265 |
| 1Y MDD | -60.36% | US#2,695/3,115 Sec#201/265 |
| Trading | ||
| Volume | 1,896,218 shares | US#1,550/3,115 Sec#158/265 |
| Trading Value | $7M | US#2,733/3,115 Sec#221/265 |
| Per Share | ||
| EPS | $-4.57 | US—/3,115 Sec—/265 |
| BPS | $3.32 | US#2,398/3,115 Sec#147/265 |
Company Info
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.